Prospective Evaluation of 68Ga-PSMA-ligand PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management

Trial Profile

Prospective Evaluation of 68Ga-PSMA-ligand PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Gallium 68 PSMA (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use
  • Acronyms ProsPERo
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 12 Jan 2017 Planned initiation date changed from 1 Sep 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top